Sang Y Kang
Examiner (ID: 16151)
Most Active Art Unit | 2315 |
Art Unit(s) | 2315 |
Total Applications | 8 |
Issued Applications | 2 |
Pending Applications | 1 |
Abandoned Applications | 5 |
Applications
Application number | Title of the application | Filing Date | Status |
---|---|---|---|
Array
(
[id] => 16252186
[patent_doc_number] => 20200261560
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-08-20
[patent_title] => PRECISION GLYCOCONJUGATES AS THERAPEUTIC TOOLS
[patent_app_type] => utility
[patent_app_number] => 16/803406
[patent_app_country] => US
[patent_app_date] => 2020-02-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 28755
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16803406
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/803406 | PRECISION GLYCOCONJUGATES AS THERAPEUTIC TOOLS | Feb 26, 2020 | Abandoned |
Array
(
[id] => 16512962
[patent_doc_number] => 20200392220
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-12-17
[patent_title] => ANTIBODY FORMULATION
[patent_app_type] => utility
[patent_app_number] => 16/798211
[patent_app_country] => US
[patent_app_date] => 2020-02-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 30160
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16798211
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/798211 | ANTIBODY FORMULATION | Feb 20, 2020 | Abandoned |
Array
(
[id] => 18910312
[patent_doc_number] => 11873281
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-01-16
[patent_title] => Conjugates of cell binding molecules with cytotoxic agents
[patent_app_type] => utility
[patent_app_number] => 16/782456
[patent_app_country] => US
[patent_app_date] => 2020-02-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 25
[patent_figures_cnt] => 30
[patent_no_of_words] => 43397
[patent_no_of_claims] => 17
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 1379
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16782456
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/782456 | Conjugates of cell binding molecules with cytotoxic agents | Feb 4, 2020 | Issued |
Array
(
[id] => 17953503
[patent_doc_number] => 11479594
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-10-25
[patent_title] => Peptides and combination of peptides for use in immunotherapy and methods for generating scaffolds for the use against pancreatic cancer and other cancers
[patent_app_type] => utility
[patent_app_number] => 16/778945
[patent_app_country] => US
[patent_app_date] => 2020-01-31
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 37
[patent_figures_cnt] => 37
[patent_no_of_words] => 62996
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 96
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16778945
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/778945 | Peptides and combination of peptides for use in immunotherapy and methods for generating scaffolds for the use against pancreatic cancer and other cancers | Jan 30, 2020 | Issued |
Array
(
[id] => 16204895
[patent_doc_number] => 20200237885
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-07-30
[patent_title] => VACCINES FOR TREATMENT AND PREVENTION OF CANCER
[patent_app_type] => utility
[patent_app_number] => 16/738637
[patent_app_country] => US
[patent_app_date] => 2020-01-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 47917
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -20
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16738637
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/738637 | VACCINES FOR TREATMENT AND PREVENTION OF CANCER | Jan 8, 2020 | Abandoned |
Array
(
[id] => 16053035
[patent_doc_number] => 20200188372
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-06-18
[patent_title] => COMBINATION OF REGORAFENIB AND PD-1/PD-L1(2) INHIBITORS FOR TREATING CANCER
[patent_app_type] => utility
[patent_app_number] => 16/731412
[patent_app_country] => US
[patent_app_date] => 2019-12-31
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 6665
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16731412
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/731412 | Combination of regorafenib and PD-1/PD-L1(2) inhibitors for treating cancer | Dec 30, 2019 | Issued |
Array
(
[id] => 15895345
[patent_doc_number] => 20200147191
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-05-14
[patent_title] => CRYOPRESERVATION OF APOPTOTIC CANCER CELLS FOR USE IN IMMUNOTHERAPY AGAINST CANCER
[patent_app_type] => utility
[patent_app_number] => 16/730667
[patent_app_country] => US
[patent_app_date] => 2019-12-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 19184
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -9
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16730667
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/730667 | CRYOPRESERVATION OF APOPTOTIC CANCER CELLS FOR USE IN IMMUNOTHERAPY AGAINST CANCER | Dec 29, 2019 | Abandoned |
Array
(
[id] => 18620438
[patent_doc_number] => 11753466
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-09-12
[patent_title] => Anti-CD166 antibodies, activatable anti-CD166 antibodies, and methods of use thereof
[patent_app_type] => utility
[patent_app_number] => 16/723809
[patent_app_country] => US
[patent_app_date] => 2019-12-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 26
[patent_figures_cnt] => 48
[patent_no_of_words] => 77800
[patent_no_of_claims] => 64
[patent_no_of_ind_claims] => 8
[patent_words_short_claim] => 208
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16723809
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/723809 | Anti-CD166 antibodies, activatable anti-CD166 antibodies, and methods of use thereof | Dec 19, 2019 | Issued |
Array
(
[id] => 15800237
[patent_doc_number] => 20200123261
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-04-23
[patent_title] => NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 16/718092
[patent_app_country] => US
[patent_app_date] => 2019-12-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 95618
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -50
[patent_words_short_claim] => 80
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16718092
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/718092 | NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF | Dec 16, 2019 | Pending |
Array
(
[id] => 17755558
[patent_doc_number] => 11395836
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-07-26
[patent_title] => Cancer antigen specific cytotoxic T cell
[patent_app_type] => utility
[patent_app_number] => 16/715695
[patent_app_country] => US
[patent_app_date] => 2019-12-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 11
[patent_figures_cnt] => 17
[patent_no_of_words] => 10816
[patent_no_of_claims] => 14
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 178
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16715695
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/715695 | Cancer antigen specific cytotoxic T cell | Dec 15, 2019 | Issued |
Array
(
[id] => 15765977
[patent_doc_number] => 20200114006
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-04-16
[patent_title] => ANTI-FIBROBLASTIC FLUOROCHEMICAL EMULSION THERAPIES
[patent_app_type] => utility
[patent_app_number] => 16/712150
[patent_app_country] => US
[patent_app_date] => 2019-12-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 7490
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -20
[patent_words_short_claim] => 30
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16712150
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/712150 | ANTI-FIBROBLASTIC FLUOROCHEMICAL EMULSION THERAPIES | Dec 11, 2019 | Pending |
Array
(
[id] => 16326895
[patent_doc_number] => 20200297860
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-09-24
[patent_title] => ERIBULIN-BASED ANTIBODY-DRUG CONJUGATES AND METHODS OF USE
[patent_app_type] => utility
[patent_app_number] => 16/702720
[patent_app_country] => US
[patent_app_date] => 2019-12-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 58663
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -24
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16702720
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/702720 | ERIBULIN-BASED ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | Dec 3, 2019 | Abandoned |
Array
(
[id] => 16090517
[patent_doc_number] => 20200199245
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-06-25
[patent_title] => MACROPINOCYTOSING HUMAN ANTI-CD46 ANTIBODIES AND TARGETED CANCER THERAPEUTICS
[patent_app_type] => utility
[patent_app_number] => 16/691417
[patent_app_country] => US
[patent_app_date] => 2019-11-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 40592
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16691417
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/691417 | MACROPINOCYTOSING HUMAN ANTI-CD46 ANTIBODIES AND TARGETED CANCER THERAPEUTICS | Nov 20, 2019 | Pending |
Array
(
[id] => 18428707
[patent_doc_number] => 11673917
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-06-13
[patent_title] => Peptides, combination of peptides, and cell based medicaments for use in immunotherapy against urinary bladder cancer and other cancers
[patent_app_type] => utility
[patent_app_number] => 16/671981
[patent_app_country] => US
[patent_app_date] => 2019-11-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 24
[patent_figures_cnt] => 27
[patent_no_of_words] => 37136
[patent_no_of_claims] => 13
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 35
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16671981
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/671981 | Peptides, combination of peptides, and cell based medicaments for use in immunotherapy against urinary bladder cancer and other cancers | Oct 31, 2019 | Issued |
Array
(
[id] => 15527187
[patent_doc_number] => 20200055899
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-02-20
[patent_title] => PEPTIDES, COMBINATION OF PEPTIDES, AND CELL BASED MEDICAMENTS FOR USE IN IMMUNOTHERAPY AGAINST URINARY BLADDER CANCER AND OTHER CANCERS
[patent_app_type] => utility
[patent_app_number] => 16/671994
[patent_app_country] => US
[patent_app_date] => 2019-11-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 38303
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 24
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16671994
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/671994 | PEPTIDES, COMBINATION OF PEPTIDES, AND CELL BASED MEDICAMENTS FOR USE IN IMMUNOTHERAPY AGAINST URINARY BLADDER CANCER AND OTHER CANCERS | Oct 31, 2019 | Abandoned |
Array
(
[id] => 15524749
[patent_doc_number] => 20200054680
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-02-20
[patent_title] => METHODS AND COMPOSITIONS FOR DOSING IN ADOPTIVE CELL THERAPY
[patent_app_type] => utility
[patent_app_number] => 16/667564
[patent_app_country] => US
[patent_app_date] => 2019-10-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 54828
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -38
[patent_words_short_claim] => 72
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16667564
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/667564 | Methods and compositions for dosing in adoptive cell therapy | Oct 28, 2019 | Issued |
Array
(
[id] => 16053235
[patent_doc_number] => 20200188472
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-06-18
[patent_title] => CONJUGATES FOR IMMUNOTHERAPY
[patent_app_type] => utility
[patent_app_number] => 16/659207
[patent_app_country] => US
[patent_app_date] => 2019-10-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 16233
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16659207
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/659207 | CONJUGATES FOR IMMUNOTHERAPY | Oct 20, 2019 | Abandoned |
Array
(
[id] => 15407991
[patent_doc_number] => 20200024317
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-01-23
[patent_title] => NOVEL PEPTIDES AND COMBINATION OF PEPTIDES AND SCAFFOLDS THEREOF FOR USE IN IMMUNOTHERAPY AGAINST COLORECTAL CARCINOMA (CRC) AND OTHER CANCERS
[patent_app_type] => utility
[patent_app_number] => 16/591158
[patent_app_country] => US
[patent_app_date] => 2019-10-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 41822
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 23
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16591158
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/591158 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES AND SCAFFOLDS THEREOF FOR USE IN IMMUNOTHERAPY AGAINST COLORECTAL CARCINOMA (CRC) AND OTHER CANCERS | Oct 1, 2019 | Abandoned |
Array
(
[id] => 17297918
[patent_doc_number] => 20210393757
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-12-23
[patent_title] => Melanoma Canine Vaccine Compositions and Methods of Use Thereof
[patent_app_type] => utility
[patent_app_number] => 17/281726
[patent_app_country] => US
[patent_app_date] => 2019-09-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10583
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -24
[patent_words_short_claim] => 39
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17281726
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/281726 | Melanoma Canine Vaccine Compositions and Methods of Use Thereof | Sep 29, 2019 | Pending |
Array
(
[id] => 18211048
[patent_doc_number] => 20230057310
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-02-23
[patent_title] => TREATMENT METHODS
[patent_app_type] => utility
[patent_app_number] => 17/280594
[patent_app_country] => US
[patent_app_date] => 2019-09-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 42158
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -46
[patent_words_short_claim] => 32
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17280594
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/280594 | TREATMENT METHODS | Sep 26, 2019 | Pending |